Tenaya Therapeutics, Inc.

NASDAQ:TNYA

Biotechnology

Healthcare
$0.31 -0.58%

-$0.00 today

Market cap
$69.95M
Beta
2.82
P/E (TTM)
-1.3
EPS (TTM)
-$0.54
52W Low $0.53High $2.35

Volume 2.77M

Average 3.79M

TNYA Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Tenaya Therapeutics, Inc.NASDAQ: TNYA

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures declines year over year

Q1 FY2026 capital expenditures of $11K (cash outflow) fell 97.1% year over year, behind the -70.9% change in trailing-twelve-month capital expenditures. Sequentially, it fell 83.6% from the prior quarter. Over 3 fiscal years it compounded at -68.9% a year.

Context

  • Capital expenditures grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -97.1% toward the trailing-twelve-month pace of -70.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$11K-83.6% QoQ
Last fiscal yearDec 2025
-$618K-39.7% YoY
LTMMar 2026
-$246K-70.9% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-97.1%——
1 year-39.7%——
3-year CAGR-68.9%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(618K) USD
Year-over-year change
+39.7%

Capital Expenditures vs competitors

How TNYA compares with its peers on the latest reported figures

  • TNYA's LTM Mar 2026 capital expenditures of $246K is the 7th largest of the 11 companies compared; the peer median is $610K.
  • Its year-over-year change of -70.9% is the 6th highest of 10, against a peer median of -41.0%.
  • Capital expenditures amounts to 109.3% of revenue for TNYA, versus a peer median of 3.0%.
TNYA Competitors Peer median
Capital Expenditures for TNYA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABEOAbeona Therapeutics Inc.LTM Mar 2026$7.51M +140.5%+294.4%51.6%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$1.95M -4.2%+1.4%5.3%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$1.77M -93.4%+82.4%2.6%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$1.57M -7.4%-18.1%—
HUMAHumacyte, Inc.LTM Mar 2026$831K -41.0%-5.5%41.2%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$389K -91.5%-40.5%3.5%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$246K -70.9%-68.9%109.3%
IMRXImmuneering CorporationLTM Mar 2026$213.21K +278.4%-42.4%—
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$22K -97.4%-65.4%0.1%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$20K -96.2%-71.9%0.1%
PYXSPyxis Oncology, Inc.LTM Mar 2026$9K —-88.8%0.1%
Peer median (excluding TNYA) $610K-41.0%-29.3%3.0%

Competitors are the stored peer set for TNYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(72.72M)(123.67M)(124.08M)(111.13M)(90.6M)
Depreciation & Amortization2.96M6.47M8.69M8.47M8.85M
Deferred Income Tax00000
Stock-Based Compensation2.95M11.47M15.31M16.5M13.05M
Change in Working Capital4.74M(849K)(5.65M)(7.93M)(2.46M)
Accounts Receivables00000
Inventory00000
Accounts Payables8.6M1.66M(3.28M)(581K)(1.43M)
Other Working Capital(3.86M)(2.51M)(2.37M)(7.35M)(1.03M)
Other Non-Cash Items1.26M2.16M3.66M3.59M2.9M
Operating Cash Flow(60.81M)(104.42M)(102.07M)(90.5M)(68.26M)
Capital Expenditures(25.12M)(20.63M)(1.24M)(1.03M)(618K)
Acquisitions (Net)00000
Purchases of Investments(213.44M)(140.48M)(56.64M)(87.07M)0
Sales of Investments0244.75M106.62M89.21M56.7M
Other Investing Activities08K(25K)17K0
Investing Cash Flow(238.56M)83.65M48.72M1.13M56.08M
Debt Repayment00000
Common Stock Issued188.54M77.39M3.87M46.76M108.41M
Common Stock Repurchased(13K)0000
Dividends Paid00000
Other Financing Activities461K380K181K987K0
Financing Cash Flow208.97M77.77M4.05M47.75M108.41M
Effect of Forex Changes00000
Net Change in Cash(90.41M)57M(49.31M)(41.62M)96.22M
Free Cash Flow(85.93M)(125.05M)(103.31M)(91.53M)(68.88M)

Tenaya Therapeutics, Inc.

NASDAQ:TNYA

Intrinsic Alpha fair value

Locked

Current Price

$0.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.